Permeability of Intestinal and Blood—Tissue Barriers in Rats for Evans Blue Dye under Conditions of Acute Intoxication with Cyclophosphamide
- 3 Downloads
Myeloablative therapy was modeled by administration of cyclophosphamide to rats in a dose of 2.1 LD50 for 14 days. Under these conditions, increased accumulation of Evans blue dye given by gavage was observed in the blood, brain, lung, liver, kidney, and ileum (by 34, 1.6, 149, 46, 30, and 6.2 times, respectively). After intravenous injection of the dye, its accumulation was increased only in the lung and ileum. Thus, simulation of myeloablation cytostatic therapy by cyclophosphamide injection to rats is associated with impairment of the intestinal and lung—blood barriers. These alterations predispose to penetration of biologically active substances from the small intestine, gastrointestinal chyme, and lungs to the blood, thus contributing to the development of the early toxic effects of cyclophosphamide.
Key Wordscyclophosphamide acute intoxication Evans blue intestinal barrier tissueblood barrier
Unable to display preview. Download preview PDF.
- 1.Legeza VI, Galeev ISh, Seleznev AB. Emetic Syndrome. St. Petersburg, 2005. Russian.Google Scholar
- 3.Manual on Experimental (Preclinical) Study of New Pharmacological Substances, Khabriev RU, ed. Moscow, 2005. RussianGoogle Scholar
- 4.Brash JT, Ruhrberg C, Fantin A. Evaluating vascular hyperpermeability- inducing agents in the skin with the Miles assay. J. Vis. Exp. 2018;(136). doi: https://doi.org/10.379/57524Google Scholar
- 5.Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA. The potential for complete and durable response in nonglia primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J. Sci. Am. 1998;4(2):110-124.Google Scholar
- 8.Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M. Long-term efficacy of reducedintensity versus myeloablative conditioning before allogenic haemopoietic cell transplantation in patients with acute myeloid laekaemia in first complete remission: retrospective follow-up open-label, randomized phase 3 trial. Lancet Haematol. 2018;5(4):e161-e169.CrossRefGoogle Scholar
- 9.Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A,Gathright GR, Yates BJ, Andrews PL. Why can’t rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS One. 2013;8(4). ID e60537. doi: https://doi.org/10.1371/journal. pone.0060537Google Scholar
- 11.Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Bolaños-Meade J, Swinnen L, Kanakry J, Luznik L, Jones RJ, Fuchs E, Ambinder R, Kasamon Y, Symons HJ. Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy. Biol. Blood Marrow Transplant. 2017;23(4):612-617.CrossRefGoogle Scholar